Top

Published in:

01-06-2015 | Case Report

Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX

Authors: Jason Zhu, Jonathan R. Strosberg, Evan Dropkin, John H. Strickler

Published in: Journal of Gastrointestinal Cancer | Issue 2/2015

Excerpt

Standard first-line treatment for poorly differentiated or high-grade neuroendocrine carcinoma (NECA) consists of combination chemotherapy with a platinum agent (either cisplatin or carboplatin) and a topoisomerase inhibitor (etoposide) [1]. This recommendation is derived from large trials in patients with small cell lung cancer, an aggressive variant of NECA, and from several small, non-randomized trials in patients with extrapulmonary NECAs [2, 3]. Recently, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) was shown to significantly improve response rates and overall survival among patients with metastatic adenocarcinoma of the pancreas [4]. We recently treated two patients with pancreatic NECA using FOLFIRINOX in the first line and in the salvage setting. …

Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799–800.CrossRefPubMedCentralPubMed

Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.CrossRefPubMed

Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.CrossRefPubMedCentralPubMed

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed

Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14:456–67.CrossRefPubMed

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMed

Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. World Health Organization classification of tumours, vol 3. Lyon: International Agency for Research on Cancer; 2010.

Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedCentralPubMed

Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814–23.CrossRefPubMed

10.

Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–52.CrossRefPubMedCentralPubMed

11.

NCCN. Neuroendocrine Tumors. 2014. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

12.

Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.CrossRefPubMed

13.

Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.PubMed

14.

Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–92.PubMed

15.

Hanna N, Bunn Jr PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.CrossRefPubMed

16.

Kenmotsu H, Niho S, Ito T, et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Lung Cancer. 2014;84:254–8.CrossRefPubMed

17.

Ferrarotto R, Testa L, Riechelmann RP, et al. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare Tumors. 2013;5:e35.CrossRefPubMedCentralPubMed

18.

Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637–42.CrossRefPubMed

19.

Kunz PL, TK, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA Ford, BaliseRR., G. A. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. ASCO Annual Meeting 2010.

20.

Venook A. P. AHK, M. A. Tempero, J. Uy, WeberT, Korn and Bergsland EK.. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008 2008 ASCO Annual Meeting Proceedings.

21.

Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–71.CrossRefPubMed

Title: Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX
Authors: Jason Zhu
Jonathan R. Strosberg
Evan Dropkin
John H. Strickler
Publication date: 01-06-2015
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 2/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-015-9689-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2015

Adjusting the Patient Positioning During Endoscopy in Diagnosis of Gastrocolic Fistula Related to Advanced Stage Gastric Malignancy

Molecular Analysis of Iranian Colorectal Cancer Patients at Risk for Lynch Syndrome: a New Molecular, Clinicopathological Feature

Female Sex Hormone Receptors in Gallbladder Cancer

Hepatobiliary Cystadenocarcinoma of the Liver with Features of Ductal Plate Malformations

Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?

High Mortality Rates After ALPPS: the Devil Is the Indication

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials